Seelos Therapeutics Inc. (NASDAQ:SEEL) Granted Patent For SLS-002 By Japanese Patent Office And SLS-005 By USPTO

Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced that the Japanese patent Office has issued it with a patent (patent number 6722453) that covers SLS-002.

Seelos receives patent for SLS-002

The patent is titled ANXIOLKYTIC COMPOSITION, FORMULATION AND METHOD USE. The issued patent covers the formulation and method that uses SLS-002 in treating patients that experience anxiety because of phobic conditions like Agoraphobia, Specific Phobia, and Social Phobia. Also, the company has received a Notice of Allowance from the Patent Office covering SLS-002 with claims covering formulation and method of use of SLS-002 in preventing anxiety in patients before dental or other medical procedures.

In June, the company released final safety data if the first phases intranasal Racemic Ketamine (SLS-002) study evaluated the pharmacodynamics/pharmacokinetics of SLS-002. Results from the study showed that SLS-002 was well tolerated and safe in all doses with the resolution of expected dissociative adverse events occurring in a higher dose group within an hour. The company’s CEO and Chairman Raj Mehra stated at the time that an hour time point for dissociative side effects meant that the therapy is differentiated truly enabling the company to evaluate SLS-002 in indications such as a first-line major depressive disorder beyond the Acute Suicidal Ideation and Behaviour.

The company plans to commence a Proof of Concept study for ASIB in two parts. The first part will be an open-label trial enrolling 16 subjects, followed by a double-blind placebo-controlled second part study of around 120 subjects.

USPTO grants Seelos a patent for SLS-005 in various neurodegenerative conditions

Recently the company also announced that the US Patent and Trademark Office had issued it with a Notice of Allowance for its application number 16/460,046 titled “TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE”.

The allowed claims under the notice cover method of use of trehalose (SLS-005) in treating different neurodegenerative conditions that include Spinocerebellar ataxia (SCA), dentatomral-pailidoluyssan atrophy (DRPLA), bulbar muscular atrophy (SBMA), progressive supranuclear palsy (PSP), Pick’s disease, frontotemporal dementia and corticobasal degenerations (CBD).